Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer

ONCOLOGY

Volumn 11, Issue 8 SUPPL., 1997, Pages 15-18

  Gradishar, William J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN CITRATE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ASTHMA; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; EDEMA; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMATITIS;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ESTROGEN ANTAGONISTS; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; REMISSION INDUCTION; TAMOXIFEN; TAXOIDS;

EID: 0030794314     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Van Oosterom AT, Schrijvers D: Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anti Cancer Drugs 6:356-368, 1995.
2. ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial of docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527-532, 1994.
3. Radvin P, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
4. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel, a new, highly antineo-plastic agent in the management of patients with anthraeycline-resistant metastatic breast cancer J Clin Oncol 13:2886-2894, 1995.
5. Guastalla JP, Bonneterre J, Fumoleau P, et al: A phase II trial of docetaxel in patients with anthracycline-resistant metastatic breast cancer (MBC) (abstract 348). Eur J Cancer 31 A: S75-S76, 1995.
6. 2 every 3 weeks as first line chemotherapy in advanced breast cancer: A second EORTC Clinical Screening Group Study (abstract 199). Ann Oncol 5(suppl 8):40, 1994.
7. Trudeau ME, Eisenhauer EA, Higgins EP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 422-428, 1996.
8. Fumoleau P, Chevallier B, Dieras V, et al: Evaluation of two doses of Taxotere (docetaxel) as first line in advanced breast cancer: EORTC Clinical Screening Group report (abstract A6221). Breast Cancer Res Treat 32:34, 1994.
9. Seidman AD, Hudis C, Crown JP, et al. Phase II evaluation of Taxotere (RP 56976, NSC 628503) as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 13:A52, 1993.
10. Chevallier B, Fumoleau P, Kerbat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995.
11. Krakowski I, Rios M, Fumoleau P, et al: Phase II first line chemotherapy (CT) study with docetaxel (Taxotere) and prophylactic premedication of fluid retention (FR) in patients (pts) with metastatic (mts) or locally advanced breast cancer (ABC)- EORTC Clinical Screening Group (CSG). Proc Am Soc Clin Oncol 14:97, 1994.
12. Bonadonna G, Veronesi U, Brambilla C, et al' Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 85:1539-1545, 1995.
13. Booser D, Frye D, Singletary S, et al: Response to induction chemotherapy for breast cancer: A prospective multimodality treatment program. Proc Am Soc Clin Oncol 11-82, 1982.
14. Calais G, Descamps P, Chapet S, et al: Primary chemotherapy and radiosurgical breast conserving treatment for patients with locally advanced operable breast cancers. Int J Radiat Oncol Biol Phys 26: 37-42, 1993.
15. Scholl S, Fourquet A, Assclain B. et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial. Eur J Cancer 30:645-52, 1994.
16. Schwartz G, Birchansky C, Komarnicky L, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994.
17. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547552, 1995.
18. Ragaz J, Knowling M, Jones G. et al: Comparability of preoperative (neoadjuvant) (pre) and postoperative (post) (TH) for locally advanced breast cancer (LABC). Proc Am Assoc Cancer Res 28:197, 1987.